Navigation Links
Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
Date:9/30/2010

settled on October 12, 2010.

In addition, warrant holders of Movetis have agreed to tender 727,911 new shares to be issued on the settlement date following the conditional exercise of warrants.

Accordingly, Shire Holdings Luxembourg S.a r.l. (a subsidiary of Shire plc) will own 99.21% of the outstanding shares of Movetis on the settlement date of the tender offer.

Squeeze-Out Procedure

Shire has decided to proceed with a squeeze-out of those shares not tendered to the offer in accordance with applicable Belgian legislation. In this regard, an additional tender offer period will open, on the same terms, on October 12, 2010 and close on November 2, 2010 at 4 pm CET.

Shares tendered into the additional tender offer are expected to be settled on November 8, 2010. Shares and warrants not tendered to the additional tender offer shall be deemed transferred to Shire Holdings Luxembourg S.a r.l. by operation of law on November 8, 2010. Payment of the offer price for shares and warrants not tendered to the additional tender offer will be deposited with the Deposito-en Consignatiekas/Caisse des Depots et Consignations in Belgium.

At the close of the reopened tender offer, the shares in Movetis will be delisted from Euronext Brussels. The last trading day will therefore be November 2, 2010.

Shire's offer is EUR19 in cash for each outstanding Movetis share.

The prospectus relating to the tender offer and the squeeze-out is available at no cost at the counters of the Receiving and Paying Agents in Belgium The Royal Bank of Scotland N.V. or by phone (+3120/4643707), KBC Securities NV, KBC Bank NV, CBC Banque SA or by phone 03/283 29 70 (KBC telecenter) or 0800/92 020 (CBC Banque). An electronic version of the prospectus is available on the following websites: http://www.kbcsecurities.be, http://www.kbc.be, http
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
2. Change of Name to Shire plc
3. Shires New Product Portfolio Delivers Strong Quarterly Performance
4. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
5. Shire plc: Change to Directors Details
6. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
7. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
8. Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
9. Shire Announces Opening of Office in Japan
10. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
11. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... York (PRWEB) December 23, 2014 According to ... Long Island Affiliate of ITRA Global, the national office market ... steady recovery. This is evidenced by the third quarter’s ... stock market. Low energy costs have held inflation down ... only negative is the housing market remaining soft. , This ...
(Date:12/24/2014)... December 24, 2014 The report expects ... 19.7% by 2019. It also provides a carefully analyzed ... and challenges for the market. , Full Copy of ... report, the global market for cell expansion will keep ... It expects this growth to be driven by rapid ...
(Date:12/24/2014)... 23, 2014 Vermillion, Inc. (Nasdaq:   ... disease, announced today that investors including Oracle Investment ... LLC and several Vermillion directors have agreed to ... Vermillion,s common stock and warrants to purchase unregistered ... placement.  Under the terms of ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... one Delaware man,s vision,comes true, Americans will become ... with breast cancer, and to get started on ... an awareness campaign in his home state this,month., ... Tumor Foundation,and early this month kicked off a ...
... Agreement with U.S. Attorney,s, Office for Eastern District of ... Settles State Cases with ... Cephalon, Inc. (Nasdaq:,CEPH) announced today it has finalized a ... for the Eastern District of,Pennsylvania, the U.S. Department of ...
... Publications --, BRITISH COLUMBIA, Canada, Sept. 29 ... VENTURE: IXS;, http://www.ixsbio.com ), a drug development company ... its Dynamic Cross Linking,(DXL(TM)) technology, announces Jeff Morhet, ... company also announces the featuring of,Mr. Morhet in ...
Cached Biology Technology:Delaware Man Spearheads Brain Tumor Awareness 2Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 2Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 3Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 4InNexus Biotechnology CEO to Present at BioContactQuebec 2008 2
(Date:12/22/2014)...  The 2014 Holiday Season may be the ... Market Intelligence reports that the long anticipated floodgates ... forecasts that intensifying demand for smart phones, tablets, ... drive a global market of 2.5 billion users ... According to Maxine Most ...
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   ... platform built for the post-password and Internet of Things ... additional seed funding. The venture round was led by ... Pantera Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey ... the new funding to expand its team and bring ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... Illinois at Chicago College of Pharmacy are attempting ... antipsychotic medication works in adults and children and ... a popular "atypical" antipsychotic medication, is used to ... disorder. , Jeffrey Bishop, assistant professor of ...
... With wheat stem sawfly natural enemies in demand, ... increasing their availability. , This fall, the ... mass-rearing parasitic wasps that attack wheat stem sawfly ... plants. The team includes entomologists David Weaver, master's ...
... tool developed at Cambridge University represents a breakthrough in ... Huntington's disease. , Researchers have developed an effective ... the disease, using an automated touch screen. It is ... more effectively the cognitive difficulties in other neurodegenerative disorders ...
Cached Biology News:Studies look at how genes affect antipsychotic drug response 2Rearing an army to save wheat 2Rearing an army to save wheat 3New technology to speed up research into Huntington's disease 2New technology to speed up research into Huntington's disease 3
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
Request Info...
...
... Agarose-HR High Resolution - ... from 50 to 1000 ... for sizing PCR fragments, ... by restriction enzyme digestion, ...
Biology Products: